Ppi-1040 | 1436673-69-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: Ppi-1040
• 英文别名: [1-[(Z)-hexadec-1-enoxy]-3-[(2-oxo-1,3,2λ5-oxazaphospholidin-2-yl)oxy]propan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
• CAS: 1436673-69-6
• 化学式: C₄₃H₇₂NO₆P
• 分子量: 730.0
• InChiKey: SKDNPCDRIUQGAL-XTJCVSPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.1
• 重原子数：
  51
• 可旋转键数：
  35
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF<br/>[FR] PROCÉDÉS POUR LA SYNTHÈSE DE PLASMALOGÈNES ET DE DÉRIVÉS DE PLASMALOGÈNES, ET UTILISATIONS THÉRAPEUTIQUES DE CEUX-CI
  申请人：PHENOMENOME DISCOVERIES INC

  公开号：WO2013071418A1

  公开（公告）日：2013-05-23

  A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.

  一种制备由化学式B表示的酯烯醇类物质及其衍生物的方法，其中R1和R2为相似或不同，源自脂肪酸；R3从氢和小的烷基组中选择。合成途径涉及制备化学式A的新型环状酯烯醇前体，以及将其转化为化学式B的酯烯醇类物质和其衍生物。还公开了通过本发明的合成途径生产的酯烯醇类物质及其衍生物的治疗用途。
• METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF
  申请人：PHENOMENOME DISCOVERIES INC.

  公开号：US20140296187A1

  公开（公告）日：2014-10-02

  A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.

  一种制备以公式B表示的鞘磷脂醇和其衍生物的方法，其中R1和R2相似或不同，来自脂肪酸；R3选自氢和小的烷基。合成路线涉及产生新的环状鞘磷脂醇前体物，其公式为A，并将其转化为公式B的鞘磷脂醇和鞘磷脂醇衍生物。本发明还揭示了所述合成路线所产生的鞘磷脂醇和其衍生物的治疗用途。
• METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN
  申请人：PHENOMENOME DISCOVERIES INC.

  公开号：US20140323749A1

  公开（公告）日：2014-10-30

  A method for preparing 13 C labeled plasmalogens as represented by Formula B: —The method involves producing a 13 C labeled cyclic plasmalogen precursor of Formula A, and conversion of the precursor to a plasmalogen of Formula B. These plasmalogens may potentially be useful in the determination of both the mechanism of action as well as the fate of plasmalogens in the body.

  一种制备以B式表示的13C标记的鞘磷脂的方法：该方法涉及生产A式的13C标记的环状鞘磷脂前体，并将前体转化为B式的鞘磷脂。这些鞘磷脂可能潜在地有助于确定鞘磷脂在体内的作用机制和命运。
• Cyclic plasmenylethanolamines
  申请人：MED-LIFE DISCOVERIES LP

  公开号：US11311560B2

  公开（公告）日：2022-04-26

  Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R1 and R2 are each, independently, a saturated, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses thereof in the treatment of plasmalogen deficiency are also described. Cyclic plasmenylethanolamines described herein may act as plasmalogen precursors which, following administration, may be converted to at least one plasmalogen species, thereby elevating the plasmalogen level in a subject.

  本文提供了式 A 的环状磷脂酰乙醇胺和磷脂酰前体，其中 R1 和 R2 各自独立地为饱和、不饱和或多不饱和烃基。此外，还介绍了治疗质卤素缺乏症的方法和用途。本文所述的环状磷脂酰乙醇胺可作为磷脂酰卤前体，给药后可转化为至少一种磷脂酰卤，从而提高受试者体内的磷脂酰卤水平。
• CYCLIC PLASMENYLETHANOLAMINES
  申请人：MED-LIFE DISCOVERIES LP

  公开号：US20210128590A1

  公开（公告）日：2021-05-06

  Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R 1 and R 2 are each, independently, a saturated, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses thereof in the treatment of plasmalogen deficiency are also described. Cyclic plasmenylethanolamines described herein may act as plasmalogen precursors which, following administration, may be converted to at least one plasmalogen species, thereby elevating the plasmalogen level in a subject.